Clinical trials: Heart Failure, Unspecified
Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had…
- Trial name
- VICTOR (NCT05093933)
- Testing
- Vericiguat
- Where
- 519 sites in United States, Argentina and 34 more
- Volunteers
- 6,106 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Preserved Ejection Fraction
Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with…
- Trial name
- ENDEAVOR (NCT04986202)
- Testing
- AZD4831
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 711 people
- Sponsor
- AstraZeneca
Congestive Heart Failure
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
- Trial name
- NCT00634309
- Testing
- Candesartan
- Volunteers
- 597 people
- Sponsor
- AstraZeneca
Hypertension, Pulmonary, Heart Failure
The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the IVC
In patients with heart failure, elevated filling pressures may contribute to symptoms while not improving cardiac output. The current study is focused on evaluating the relationship between exercise capacity, pulmonary pressures…
- Trial name
- NCT02984631
- Testing
- Preventing pulm HTN during exercise
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cardioflow Technologies, LLC
Sleep Disordered Breathing, Congestive Heart Failure
Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep
Respiratory insufficiencies during sleep can lead to reductions in the level of oxygen in the blood during the night, which has been shown to contribute to a range of morbidities.
- Trial name
- NCT02152566
- Testing
- Nasal High flow therapy device
- Where
- 2 sites in New Zealand
- Volunteers
- 6 people
- Sponsor
- Fisher and Paykel Healthcare
Chronic Heart Failure, Central Sleep Apnea
French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS)
The purpose of FACE study is to provide in routine practice complementary long-term data on the mortality and morbidity of Chronic Heart Failure (CHF) patients with Central Sleep Apnea eligible for Adaptative Servo-Ventilation…
- Trial name
- FACE (NCT01831128)
- Testing
- ASV Treatment
- Where
- 18 sites in France
- Volunteers
- 509 people
- Sponsor
- ResMed
Heart Failure
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
The proposed study aims to compare the pharmacokinetics and bioavailability of intravenous and subcutaneous Furosemide. Although these regimens are not intended to be bioequivalent, they are both expected to achieve therapeutic…
- Trial name
- NCT04384653
- Testing
- Furosemide Injection Solution for subcutaneous administration (80 mg), Furosemide Injection, USP, Medfusion 3500 (v6) precision infusion pump
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SQ Innovation, Inc.
Heart Failure
Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial
Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF) refractory to optimal medical management, in presence of a depressed left ventricular (LV) ejection fraction and a wide QRS complex.
- Trial name
- V3 (NCT01059175)
- Testing
- Additional Endocardial or Epicardial LV Lead, CRT-P or CRT-D
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Reveal LINQ™ Heart Failure
The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients with heart failure by assessing the relationship between changes in LINQ™ derived data and other physiologic parameters with subsequent…
- Trial name
- LINQ HF (NCT02758301)
- Testing
- Reveal LINQ™ Insertable Cardiac Monitor (ICM)
- Where
- 19 sites in United States
- Volunteers
- 112 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors
The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHF platform to recommend optimal titration of Guideline-Directed Medical Therapy (GDMT)…
- Trial name
- AIM-POWER (NCT04191330)
- Testing
- BiovitalsHF
- Where
- 14 sites in United States
- Volunteers
- 122 people
- Sponsor
- Biofourmis Inc.
Heart Failure, Heart Failure NYHA Class II
Implementation and Cost-evaluation of a Smartphone-based Telemonitoring and Digital Support in Patients With HF
The BEDICARE-HF study aims to go further in the research on digital support. The objectives of this study are to demonstrate the feasibility, acceptability, adoption, sustainability and safety of a of a smartphone-based digital…
- Conditions
- Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- BEDICARE-HF (NCT05487365)
- Testing
- Comunicare Solutions Smartphone Application, Completing a quality of life (QOL)-questionnaire
- Where
- Belgium
- Volunteers
- 330 people
- Sponsor
- Comunicare Solutions SA
Heart Failure
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration
AZD9977 is an oral, selective mineralocorticoid receptor (MR) modulator. AZD9977 is a partial antagonist and partial agonist in reporter gene assays and has a different interaction pattern with the MR compared to eplerenone.
- Trial name
- NCT03801967
- Testing
- AZD9977
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
A Study to Assess Safety and Efficacy of a Novel Patch Infusor Device and Novel SUBCUTaneous Furosemide Formulation Combination in Patients With Heart Failure
This is a single-centre, prospective, open-label, non-comparative clinical trial assessing the on-body performance of an investigational drug delivery device (SQIN-Infusor) in patients hospitalised due to HF.
- Trial name
- SUBCUT-HF I (NCT04846816)
- Testing
- SQIN-01
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- SQ Innovation, Inc.
Heart Failure
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body.
- Trial name
- NCT04722484
- Testing
- Vericiguat (BAY1021189)
- Where
- Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Congestive Heart Failure, Chronic Heart Failure
Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS
This is a randomized, open-label, three-way crossover design study with 3 treatment groups:TREATMENT A: Furosemide;TREATMENT B: Nesiritide administered IV bolus, followed by an infusion for 6 hours;TREATMENT C: Treatment B for at…
- Trial name
- NCT00652652
- Testing
- nesiritide, furosemide
- Sponsor
- Scios, Inc.
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Congestive Heart Failure
Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the…
- Trial name
- NCT00785044
- Testing
- I-123 mIBG
- Where
- United States
- Volunteers
- 471 people
- Sponsor
- GE Healthcare
Heart Failure
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic…
- Trial name
- ARTS-HF (NCT01807221)
- Testing
- Finerenone (BAY94-8862), Inspra (eplerenone)
- Where
- 172 sites in United States, Australia and 23 more
- Volunteers
- 1,066 people
- Sponsor
- Bayer
Heart Failure
Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart Failure
Evaluate the pharmacokinetic and pharmacodynamic characteristics of Jia Shen Tablets in patients with Chronic Heart Failure.
- Trial name
- NCT06348498
- Testing
- Jia Shen Tablet
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure
Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant
The purpose of this study is to obtain human heart tissue after treatment with Anginera to determine its effect on a variety of things that might indicate improvement in heart function.
- Trial name
- NCT00364598
- Testing
- Anginera, a human tissue replacement therapy
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Theregen, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.